Personalized Cancer Care:
A Look at Targeted Treatments
This piece is adapted from a previous webinar
featuring Best Doctors Experts…
George Demetri, MD
Director, Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute
Senior Vice President, Experimental Therapeutics at Dana-Farber Cancer Institute
Director, Ludwig Center at Harvard
Professor of Medicine, Harvard Medical School
Michael J. Birrer, MD, PhD
Director, Medical Gynecologic Oncology at Massachusetts General Hospital
Director, Gynecologic Oncology Research Program at Massachusetts General Hospital
Professor of Medicine, Harvard Medical School
Did you know?
Did you know?
About 1,658,370 new
cancer cases are expected
to be diagnosed in 2015
compared to an estimated
1,665,540 cases in 2014.
Did you know?
About 1,658,370 new
cancer cases are expected
to be diagnosed in 2015
compared to an estimated
1,665,540 cases in 2014.
Survival statistics vary
greatly by cancer types
and stage at diagnosis. The
5-year relative survival
rate for all cancers
diagnosed in 2004-2010
was 68%, up from 49%,
partly due to both earlier
diagnosis of certain
cancers and improvements
in treatment.
*According to American Cancer Society www.cancer.org
American Cancer Society’s Cancer Treatment & Survivorship Facts & Figures 2014-2015
American Cancer Society’s Cancer Facts & Figures 2015
American Cancer Society’s Cancer Facts & Figures 2014
WHAT IS PERSONALIZED
CANCER CARE?
Cancer is not one disease.
It’s hundreds of different
diseases.
Cancer is not one disease.
It’s hundreds of different
diseases.
Personalized cancer care is a way of
approaching an individual’s treatment plan
by looking at the genetic makeup and the
biology of the patient’s tumor to identify
the best treatment plan for the individual.
HOW DOES IT DIFFER FROM
PRIOR CANCER CARE?
We’ve gained a better understanding
of how each person’s tumor is unique
and how each individual is unique.
Years ago there were really only three
options for treatment:
These could occasionally cure certain types of
cancer in people but the side effects were not
small.
chemotherapy radiation surgery
Today doctors are matching patients much
more specifically to types of treatments.
By really going after what makes the
cancer different than the person,
researchers are seeing less side effects
and better effectiveness for patients.
WHAT TARGETED CANCER TREATMENTS
ARE CURRENTLY AVAILABLE?
ARE MOST FDA APPROVED?
In the past, we’ve had drugs that treated
general characteristics of the tumor cell.
For instance, it was known that tumor cells
grow fast and they divide fast. So agents
were used that would non-specifically go
after the dividing process of the cancer
cell.
Targeted treatments, on the other hand,
are now aimed at a specific target in the
tumor’s cell. These specific targets are
associated with the cancer process.
Targeted treatments take advantage of the
characteristics that make the cancer cells
different from healthy cells.
Targeted cancer treatments are
available for many different
types of cancers.
The number of drugs the FDA is
approving now is happening at
record-breaking speed.
WHICH CANCER TYPE IS MAKING
THE BIGGEST STRIDES IN TERMS OF
TARGETED THERAPY?
It’s interestingly spread out through
most types of human cancers.
The leukemias and other types of
blood cancers have had a number of
targeted drugs developed.
The FDA is working closely with
the academic world, as well as
with the private sector to make
sure that effective drugs are
getting developed and getting
developed quickly.
Researchers are finding the
same targeted therapy drug
can work with several
different types of cancer.
For example,
brain, cervix and
colorectal cancer are
all being treated with
the FDA-approved
drug Bevacizumab.
In the past, because of the
difficulty of developing drugs and
the cost of the process, rare tumor
types, such as giant cell tumor of
the bone, were unfortunately often
overlooked for clinical trial.
Now, because development is moving incredibly
fast, agents and targeted therapies are being
found that are effective at treating extremely
rare tumor types.
This, in part, has been made easier by
technology’s ability to link communities of
people and find patterns to lead to new
drug development.
Cervical cancer, which has been historically difficult
to treat, now has an FDA-approved targeted therapy.
Ipilimumab was developed to treat melanoma. This
type of drug targets the immune system to fight the
cancer for us.
An entire disease has been turned
around with these types of therapies
and immunotherapy and has
completely revolutionized doctors’
approaches to that disease.
HOW DO YOU USE TARGETED
TREATMENTS TO EFFECTIVELY
PERSONALIZE CANCER CARE?
In general, the practicing clinician has to:
• be aware of the way the patient is presenting
• the stage of the disease
• the standard options available
• the molecular genotype of the tumor
• if the patient could match for a targeted therapy
Part of the clinician’s
responsibility is to know
these factors.
We have the ability to mix and
match therapeutic approaches
with the goal of optimizing
response and minimizing toxicity.
The clinician’s job is to help interpret
what is the molecular noise versus
what is the meaningful target that can
either put the patient on a clinical trial
or identify them for standard care.
There’s a huge interest in doing DNA tests on
tumors.
The answer to cancer for roughly 20% of those
people may be hidden in those genes, and
understanding the gene code itself can be life-
saving. However, that’s the minority of cases
still.
What we know today may not necessarily
be accurate six months from now.
A couple of years ago there were no
targeted treatments for ovarian cancer.
Now there are several.
That’s why it is the role of the
physician to be the expert in
advising patients and looking
at the patient as an individual.
I HEAR A LOT ABOUT NEW
TESTS ON TUMOR DNA.
SHOULD I HAVE THOSE?
The situation of the patient makes a
big difference here.
Plus, the tools used today might be
different a few years from now. The
tumor might change as well.
The question should be asked if a
molecular analysis will change the
course of treatment.
Will it send patients to clinical trial?
If it does, then it may be considered.
Molecular tumor boards
involve bringing a number of
experts into a room, looking
at a patient’s results and
determining as a team what
they think is best for the
patient and which one of the
identified targets could be
treated with an FDA-
approved targeted therapy
or a clinical trial.
Along this topic, there has also been a shift
toward molecular tumor boards.
WHAT ARE THE
LIMITATIONS OF
TARGETED CANCER
TREATMENT?
We need to recognize that,
although targeted therapy
has been a boon for cancer
treatment, it’s not
necessarily a cure-all.
Tumor cells are clever…
– they can develop resistance to targeted therapies
– the tumor can disappear
– the tumor can re-mutate
There are a variety of responses from the cancer
cell to survive even with the targeted therapy.
Targeted treatments are not without side
effects.
The advantage of targeted therapy is to find a subset of
patients who will benefit, a subset of tumors to
respond. That doesn’t mean they don’t have toxicity.
One more item to note is that many types of cancer
can be treated with standard treatments, such as
chemo and radiation. The goal of targeted therapy
is not to completely defer from these standard
therapies just because targeted therapy is the new
talked-about thing. It’s really about taking the
whole person into account, and that’s where the
details really do matter.
WHERE CAN I GO TO FIND
OUT MORE INFORMATION?
How do you use targeted
treatments to effectively
personalize cancer care?
Reputable sites for accurate information on cancer
statistics:
American Cancer Society: www.cancer.org
The National Cancer Institute: www.cancer.gov
American Society of Clinical Oncology: www.asco.org
Other reliable sources of information are professional
nonprofit organizations within the specific cancer type.
For instance, Ovarian Cancer National Alliance is an
organization within ovarian cancer and a good source
for information. Additionally, www.cancer.net has
subgroup-specific disease information.
www.bestdoctors.com

More Related Content

PPTX
Anti cancer treatments
PDF
Advances in lung cancer research
PPTX
An Overview of Targeted Therapy Drugs
PPTX
Targeted Therapies in Cancer
PPTX
1. introduction of chemotherapy of cancer
PDF
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
PPTX
Principles of chemotherapy(types, indications and complications)
PPTX
General principles in chemotherapy of cancer
Anti cancer treatments
Advances in lung cancer research
An Overview of Targeted Therapy Drugs
Targeted Therapies in Cancer
1. introduction of chemotherapy of cancer
Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Manag...
Principles of chemotherapy(types, indications and complications)
General principles in chemotherapy of cancer

What's hot (19)

PPTX
Molecular targeted therapies 2
PPTX
Immunotherapy of lung cancer copy
PDF
Integrative Cancer - New theories and Advances in Treatment From Hippocrates ...
PPTX
Presentation on cancer
PPT
TARGETED DRUG DELIVERY IN CANCER
PDF
Cancer treatment
PPTX
Molecular approaches in tumor therapy
PPTX
Cancer and Anticancer drugs
PPTX
Chapter 26 chemoprevention of cancer
PDF
Naturopathic Oncology Slideshare316
PPT
CHEMOTHERAPY IN CANCERS
PPTX
Cancer Cells and anticancer effect of some plants and materials
PPTX
Cancer Chemoprevention and Molecular Targeting Drug Delivery for Cancer
PPT
Targeted Therapy in Cancer
PPT
Advancements in Cancer Research with Special Reference to Pathogenesis and Di...
PPTX
Group 2 - cell cycle and chemotherapy
PPT
Cancer biology
PDF
Cancer chemoprevention with dietary phytochemicals
PDF
Immunotherapy the Present and Future of Cancer Treatment
Molecular targeted therapies 2
Immunotherapy of lung cancer copy
Integrative Cancer - New theories and Advances in Treatment From Hippocrates ...
Presentation on cancer
TARGETED DRUG DELIVERY IN CANCER
Cancer treatment
Molecular approaches in tumor therapy
Cancer and Anticancer drugs
Chapter 26 chemoprevention of cancer
Naturopathic Oncology Slideshare316
CHEMOTHERAPY IN CANCERS
Cancer Cells and anticancer effect of some plants and materials
Cancer Chemoprevention and Molecular Targeting Drug Delivery for Cancer
Targeted Therapy in Cancer
Advancements in Cancer Research with Special Reference to Pathogenesis and Di...
Group 2 - cell cycle and chemotherapy
Cancer biology
Cancer chemoprevention with dietary phytochemicals
Immunotherapy the Present and Future of Cancer Treatment
Ad

Similar to Personalized Cancer Care (20)

PPTX
Rare Cancers: The Time to Act is Now
PPTX
Big Data OncoAnalytics Architecture
PPTX
CANCER basics and advanced therapeutics.pptx
PPTX
10 years of biosimilars who benefits (1)
PDF
Oncology_WP_d02_web
PDF
Tomorrows path-to-improved-early-phase-oncology-drug-development
PPTX
PN Lesson 3 Cancer Basics 2.pptx in English
PPTX
Oncology Care Clinical Review For Clinical Program Managers
PPTX
PN Lesson 3 Cancer Basics.pptx
PDF
SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...
PDF
Targeted Therapy In Translational Cancer Research 1st Edition Apostoliamaria ...
PDF
Innovative clinical trial designs
PPTX
Precision Medicine: Opportunities and Challenges for Clinical Trials
PDF
Development of Novel Targeted Drugs: Which Target? by Eric Raymond
PPTX
Oncology.pptx
PDF
Customizing Cancer Treatments: Engineering Patient Specific Therapies (www.ki...
PPTX
Types of Cancer Treatment.pptx
PDF
Precision Medicine in Oncology
PDF
7IJMPD-28-Cancer.pdf-Cancer: A review IJMPD
Rare Cancers: The Time to Act is Now
Big Data OncoAnalytics Architecture
CANCER basics and advanced therapeutics.pptx
10 years of biosimilars who benefits (1)
Oncology_WP_d02_web
Tomorrows path-to-improved-early-phase-oncology-drug-development
PN Lesson 3 Cancer Basics 2.pptx in English
Oncology Care Clinical Review For Clinical Program Managers
PN Lesson 3 Cancer Basics.pptx
SHARE: Report Back from Annual Meeting of American Association of Cancer Rese...
Targeted Therapy In Translational Cancer Research 1st Edition Apostoliamaria ...
Innovative clinical trial designs
Precision Medicine: Opportunities and Challenges for Clinical Trials
Development of Novel Targeted Drugs: Which Target? by Eric Raymond
Oncology.pptx
Customizing Cancer Treatments: Engineering Patient Specific Therapies (www.ki...
Types of Cancer Treatment.pptx
Precision Medicine in Oncology
7IJMPD-28-Cancer.pdf-Cancer: A review IJMPD
Ad

Recently uploaded (20)

PPTX
Emotional Well Being & Conflict Resolution_VKV.pptx
PPTX
Conflict Management: Defining conflict and understanding why it occurs is t...
PDF
Indonesian Healthtech Innovation_11Sep2019_Industry_Geraldine Seow_1.pdf
PPTX
Case report session Apendisitis Akut people.pptx
PPT
toxicosis in pregnancy preeclampcia eclampcia.ppt
PPT
NEPHROTIC SYNDROME POWER POINT PRESENTATION
PPTX
Brucellosis. treatment in Uganda. Group II.pptx
PPTX
Symphosium Dr saurab ad Dr. Khushbu.pptx
PDF
CSF rhinorrhea its cause management .pptx
PPTX
Biomechanical preparation in primary teeth – Instrumentation and seminar 5 (2...
PDF
ICU Main Equipments and its explanations
PPT
FRACTURE CLASSIFICATION AND MANAGEMENT..
PPTX
SlideEgg_100085- World Mental Health Day.pptx
PDF
Dental Implants Review : A detailed Review
PPTX
Seizures in paediatrics as a big cause of morbidity.pptx
DOCX
Advanced Nursing Procedures.....realted to advance nursing practice M.Sc. 1st...
PPTX
dr vivek orho post op pain.pptxhhhhhhhhhhh
PDF
odontologia na oncologia - carie de radiação
PPTX
(PWD) Persons with intellectual disabilities ACT - 1.pptx
PPTX
Maternal and child health. The normal new born.pptx
Emotional Well Being & Conflict Resolution_VKV.pptx
Conflict Management: Defining conflict and understanding why it occurs is t...
Indonesian Healthtech Innovation_11Sep2019_Industry_Geraldine Seow_1.pdf
Case report session Apendisitis Akut people.pptx
toxicosis in pregnancy preeclampcia eclampcia.ppt
NEPHROTIC SYNDROME POWER POINT PRESENTATION
Brucellosis. treatment in Uganda. Group II.pptx
Symphosium Dr saurab ad Dr. Khushbu.pptx
CSF rhinorrhea its cause management .pptx
Biomechanical preparation in primary teeth – Instrumentation and seminar 5 (2...
ICU Main Equipments and its explanations
FRACTURE CLASSIFICATION AND MANAGEMENT..
SlideEgg_100085- World Mental Health Day.pptx
Dental Implants Review : A detailed Review
Seizures in paediatrics as a big cause of morbidity.pptx
Advanced Nursing Procedures.....realted to advance nursing practice M.Sc. 1st...
dr vivek orho post op pain.pptxhhhhhhhhhhh
odontologia na oncologia - carie de radiação
(PWD) Persons with intellectual disabilities ACT - 1.pptx
Maternal and child health. The normal new born.pptx

Personalized Cancer Care

  • 1. Personalized Cancer Care: A Look at Targeted Treatments
  • 2. This piece is adapted from a previous webinar featuring Best Doctors Experts… George Demetri, MD Director, Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute Senior Vice President, Experimental Therapeutics at Dana-Farber Cancer Institute Director, Ludwig Center at Harvard Professor of Medicine, Harvard Medical School Michael J. Birrer, MD, PhD Director, Medical Gynecologic Oncology at Massachusetts General Hospital Director, Gynecologic Oncology Research Program at Massachusetts General Hospital Professor of Medicine, Harvard Medical School
  • 4. Did you know? About 1,658,370 new cancer cases are expected to be diagnosed in 2015 compared to an estimated 1,665,540 cases in 2014.
  • 5. Did you know? About 1,658,370 new cancer cases are expected to be diagnosed in 2015 compared to an estimated 1,665,540 cases in 2014. Survival statistics vary greatly by cancer types and stage at diagnosis. The 5-year relative survival rate for all cancers diagnosed in 2004-2010 was 68%, up from 49%, partly due to both earlier diagnosis of certain cancers and improvements in treatment. *According to American Cancer Society www.cancer.org American Cancer Society’s Cancer Treatment & Survivorship Facts & Figures 2014-2015 American Cancer Society’s Cancer Facts & Figures 2015 American Cancer Society’s Cancer Facts & Figures 2014
  • 7. Cancer is not one disease. It’s hundreds of different diseases.
  • 8. Cancer is not one disease. It’s hundreds of different diseases.
  • 9. Personalized cancer care is a way of approaching an individual’s treatment plan by looking at the genetic makeup and the biology of the patient’s tumor to identify the best treatment plan for the individual.
  • 10. HOW DOES IT DIFFER FROM PRIOR CANCER CARE?
  • 11. We’ve gained a better understanding of how each person’s tumor is unique and how each individual is unique.
  • 12. Years ago there were really only three options for treatment: These could occasionally cure certain types of cancer in people but the side effects were not small. chemotherapy radiation surgery
  • 13. Today doctors are matching patients much more specifically to types of treatments. By really going after what makes the cancer different than the person, researchers are seeing less side effects and better effectiveness for patients.
  • 14. WHAT TARGETED CANCER TREATMENTS ARE CURRENTLY AVAILABLE? ARE MOST FDA APPROVED?
  • 15. In the past, we’ve had drugs that treated general characteristics of the tumor cell. For instance, it was known that tumor cells grow fast and they divide fast. So agents were used that would non-specifically go after the dividing process of the cancer cell.
  • 16. Targeted treatments, on the other hand, are now aimed at a specific target in the tumor’s cell. These specific targets are associated with the cancer process. Targeted treatments take advantage of the characteristics that make the cancer cells different from healthy cells.
  • 17. Targeted cancer treatments are available for many different types of cancers. The number of drugs the FDA is approving now is happening at record-breaking speed.
  • 18. WHICH CANCER TYPE IS MAKING THE BIGGEST STRIDES IN TERMS OF TARGETED THERAPY?
  • 19. It’s interestingly spread out through most types of human cancers. The leukemias and other types of blood cancers have had a number of targeted drugs developed.
  • 20. The FDA is working closely with the academic world, as well as with the private sector to make sure that effective drugs are getting developed and getting developed quickly.
  • 21. Researchers are finding the same targeted therapy drug can work with several different types of cancer.
  • 22. For example, brain, cervix and colorectal cancer are all being treated with the FDA-approved drug Bevacizumab.
  • 23. In the past, because of the difficulty of developing drugs and the cost of the process, rare tumor types, such as giant cell tumor of the bone, were unfortunately often overlooked for clinical trial.
  • 24. Now, because development is moving incredibly fast, agents and targeted therapies are being found that are effective at treating extremely rare tumor types.
  • 25. This, in part, has been made easier by technology’s ability to link communities of people and find patterns to lead to new drug development. Cervical cancer, which has been historically difficult to treat, now has an FDA-approved targeted therapy. Ipilimumab was developed to treat melanoma. This type of drug targets the immune system to fight the cancer for us.
  • 26. An entire disease has been turned around with these types of therapies and immunotherapy and has completely revolutionized doctors’ approaches to that disease.
  • 27. HOW DO YOU USE TARGETED TREATMENTS TO EFFECTIVELY PERSONALIZE CANCER CARE?
  • 28. In general, the practicing clinician has to: • be aware of the way the patient is presenting • the stage of the disease • the standard options available • the molecular genotype of the tumor • if the patient could match for a targeted therapy
  • 29. Part of the clinician’s responsibility is to know these factors.
  • 30. We have the ability to mix and match therapeutic approaches with the goal of optimizing response and minimizing toxicity.
  • 31. The clinician’s job is to help interpret what is the molecular noise versus what is the meaningful target that can either put the patient on a clinical trial or identify them for standard care.
  • 32. There’s a huge interest in doing DNA tests on tumors. The answer to cancer for roughly 20% of those people may be hidden in those genes, and understanding the gene code itself can be life- saving. However, that’s the minority of cases still.
  • 33. What we know today may not necessarily be accurate six months from now. A couple of years ago there were no targeted treatments for ovarian cancer. Now there are several.
  • 34. That’s why it is the role of the physician to be the expert in advising patients and looking at the patient as an individual.
  • 35. I HEAR A LOT ABOUT NEW TESTS ON TUMOR DNA. SHOULD I HAVE THOSE?
  • 36. The situation of the patient makes a big difference here. Plus, the tools used today might be different a few years from now. The tumor might change as well.
  • 37. The question should be asked if a molecular analysis will change the course of treatment. Will it send patients to clinical trial? If it does, then it may be considered.
  • 38. Molecular tumor boards involve bringing a number of experts into a room, looking at a patient’s results and determining as a team what they think is best for the patient and which one of the identified targets could be treated with an FDA- approved targeted therapy or a clinical trial. Along this topic, there has also been a shift toward molecular tumor boards.
  • 39. WHAT ARE THE LIMITATIONS OF TARGETED CANCER TREATMENT?
  • 40. We need to recognize that, although targeted therapy has been a boon for cancer treatment, it’s not necessarily a cure-all.
  • 41. Tumor cells are clever… – they can develop resistance to targeted therapies – the tumor can disappear – the tumor can re-mutate There are a variety of responses from the cancer cell to survive even with the targeted therapy.
  • 42. Targeted treatments are not without side effects. The advantage of targeted therapy is to find a subset of patients who will benefit, a subset of tumors to respond. That doesn’t mean they don’t have toxicity.
  • 43. One more item to note is that many types of cancer can be treated with standard treatments, such as chemo and radiation. The goal of targeted therapy is not to completely defer from these standard therapies just because targeted therapy is the new talked-about thing. It’s really about taking the whole person into account, and that’s where the details really do matter.
  • 44. WHERE CAN I GO TO FIND OUT MORE INFORMATION?
  • 45. How do you use targeted treatments to effectively personalize cancer care? Reputable sites for accurate information on cancer statistics: American Cancer Society: www.cancer.org The National Cancer Institute: www.cancer.gov American Society of Clinical Oncology: www.asco.org Other reliable sources of information are professional nonprofit organizations within the specific cancer type. For instance, Ovarian Cancer National Alliance is an organization within ovarian cancer and a good source for information. Additionally, www.cancer.net has subgroup-specific disease information.